177 related articles for article (PubMed ID: 23234300)
1. Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion.
Lindqvist O; Lundquist G; Dickman A; Bükki J; Lunder U; Hagelin CL; Rasmussen BH; Sauter S; Tishelman C; Fürst CJ;
J Palliat Med; 2013 Jan; 16(1):38-43. PubMed ID: 23234300
[TBL] [Abstract][Full Text] [Related]
2. Respiratory tract secretions in the dying patient: a comparison between glycopyrronium and hyoscine hydrobromide.
Hugel H; Ellershaw J; Gambles M
J Palliat Med; 2006 Apr; 9(2):279-84. PubMed ID: 16629557
[TBL] [Abstract][Full Text] [Related]
3. Core palliative medicines: meeting the needs of non-complex community patients.
Tait P; Morris B; To T
Aust Fam Physician; 2014; 43(1):29-32. PubMed ID: 24563890
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol.
Franken LG; de Winter BC; van Esch HJ; van Zuylen L; Baar FP; Tibboel D; Mathôt RA; van Gelder T; Koch BC
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):669-80. PubMed ID: 27081769
[TBL] [Abstract][Full Text] [Related]
5. How is agitation and restlessness managed in the last 24 h of life in patients whose care is supported by the Liverpool care pathway for the dying patient?
Gambles M; McGlinchey T; Latten R; Dickman A; Lowe D; Ellershaw JE
BMJ Support Palliat Care; 2011 Dec; 1(3):329-33. PubMed ID: 24653479
[TBL] [Abstract][Full Text] [Related]
6. Strategic pain management: the identification and development of the IAHPC opioid essential prescription package.
Vignaroli E; Bennett MI; Nekolaichuk C; De Lima L; Wenk R; Ripamonti CI; Bruera E
J Palliat Med; 2012 Feb; 15(2):186-91. PubMed ID: 22014206
[TBL] [Abstract][Full Text] [Related]
7. A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle.
Back IN; Jenkins K; Blower A; Beckhelling J
Palliat Med; 2001 Jul; 15(4):329-36. PubMed ID: 12054150
[TBL] [Abstract][Full Text] [Related]
8. Treatment of terminal restlessness: a review of the evidence.
Kehl KA
J Pain Palliat Care Pharmacother; 2004; 18(1):5-30. PubMed ID: 15148006
[TBL] [Abstract][Full Text] [Related]
9. [Frequency of symptoms and drug treatment among dying patients in the last 24 hours of life at Landspitali - The National University Hospital of Iceland and in nursing homes].
Halfdanardottir SI; Olafsdottir KL; Sigurdardottir V
Laeknabladid; 2017 Mai; 103(5):223-228. PubMed ID: 28489007
[TBL] [Abstract][Full Text] [Related]
10. The use of midazolam and haloperidol in cancer patients at the end of life.
Radha Krishna LK; Poulose VJ; Goh C
Singapore Med J; 2012 Jan; 53(1):62-6. PubMed ID: 22252186
[TBL] [Abstract][Full Text] [Related]
11. Audit of three antimuscarinic drugs for managing retained secretions.
Hughes A; Wilcock A; Corcoran R; Lucas V; King A
Palliat Med; 2000 May; 14(3):221-2. PubMed ID: 10858832
[No Abstract] [Full Text] [Related]
12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
13. Palliative care: an update on "terminal restlessness".
Burke AL
Med J Aust; 1997 Jan; 166(1):39-42. PubMed ID: 9006613
[TBL] [Abstract][Full Text] [Related]
14. A protocol for the acute control of agitation in palliative care: a preliminary report.
Gonçalves F; Almeida A; Teixeira S; Pereira S; Edra N
Am J Hosp Palliat Care; 2012 Nov; 29(7):522-4. PubMed ID: 22363035
[TBL] [Abstract][Full Text] [Related]
15. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer.
Navigante AH; Cerchietti LC; Castro MA; Lutteral MA; Cabalar ME
J Pain Symptom Manage; 2006 Jan; 31(1):38-47. PubMed ID: 16442481
[TBL] [Abstract][Full Text] [Related]
16. Discussions about palliative sedation in hospice: Frequency, timing and factors associated with patient involvement.
Ingravallo F; de Nooijer K; Pucci V; Casini C; Miccinesi G; Rietjens JAC; Morino P
Eur J Cancer Care (Engl); 2019 May; 28(3):e13019. PubMed ID: 30773765
[TBL] [Abstract][Full Text] [Related]
17. Morphine, haloperidol and hyoscine N-butyl bromide combined in s.c. infusion solutions: compatibility and stability. Evaluation in terminal oncology patients.
Negro S; Reyes R; Azuara ML; Sánchez Y; Barcia E
Int J Pharm; 2006 Jan; 307(2):278-84. PubMed ID: 16297583
[TBL] [Abstract][Full Text] [Related]
18. Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group.
Douglas C; Murtagh FE; Chambers EJ; Howse M; Ellershaw J
Palliat Med; 2009 Mar; 23(2):103-10. PubMed ID: 19273566
[TBL] [Abstract][Full Text] [Related]
19. Psychotropic drugs for terminally ill patients with respiratory disease.
Kanemoto K; Satoh H; Kagohashi K; Kurishima K; Ishikawa H; Ohtsuka M
Tuberk Toraks; 2007; 55(1):5-10. PubMed ID: 17401788
[TBL] [Abstract][Full Text] [Related]
20. Components and principles of a pediatric palliative care consultation: results of a Delphi study.
Bradford N; Herbert A; Mott C; Armfield N; Young J; Smith A
J Palliat Med; 2014 Nov; 17(11):1206-13. PubMed ID: 25006759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
